Published in Blood on April 07, 2011
Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol (2011) 1.70
Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst (2014) 1.68
MicroRNA 142-3p mediates post-transcriptional regulation of D1 dopamine receptor expression. PLoS One (2012) 1.26
MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int (2014) 1.11
MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins. J Biol Chem (2014) 1.10
MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol (2012) 1.06
Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis (2013) 1.05
PU.1-dependent transcriptional regulation of miR-142 contributes to its hematopoietic cell-specific expression and modulation of IL-6. J Immunol (2013) 1.04
Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. EMBO Mol Med (2012) 0.99
Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. J Clin Invest (2013) 0.98
miR-142-3p regulates the formation and differentiation of hematopoietic stem cells in vertebrates. Cell Res (2013) 0.97
MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood (2015) 0.94
MicroRNAs in the regulation of TLR and RIG-I pathways. Cell Mol Immunol (2012) 0.92
Mature T cell responses are controlled by microRNA-142. J Clin Invest (2015) 0.92
miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun (2015) 0.91
microRNA-mediated regulation of innate immune response in rheumatic diseases. Arthritis Res Ther (2013) 0.91
Fingerprinting of the TLR4-induced acute inflammatory response. Exp Mol Pathol (2012) 0.86
Human autophagy gene ATG16L1 is post-transcriptionally regulated by MIR142-3p. Autophagy (2014) 0.86
RNA regulators of host immunity and pathogen adaptive responses in the oral cavity. Microbes Infect (2015) 0.84
Actin-binding protein regulation by microRNAs as a novel microbial strategy to modulate phagocytosis by host cells: the case of N-Wasp and miR-142-3p. Front Cell Infect Microbiol (2013) 0.84
MiR-152 may silence translation of CaMK II and induce spontaneous immune tolerance in mouse liver transplantation. PLoS One (2014) 0.83
Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. Transpl Immunol (2013) 0.83
Next generation treatment of acute graft-versus-host disease. Leukemia (2014) 0.83
Alterations of dendritic cells in sepsis: featured role in immunoparalysis. Biomed Res Int (2015) 0.82
MicroRNA regulation of integrins. Transl Res (2013) 0.82
MicroRNAs in normal and psoriatic skin. Physiol Genomics (2013) 0.82
MicroRNA-142-3p Inhibits Chondrocyte Apoptosis and Inflammation in Osteoarthritis by Targeting HMGB1. Inflammation (2016) 0.81
Functional regulation of monocyte-derived dendritic cells by microRNAs. Protein Cell (2012) 0.81
MicroRNA-155 induces differentiation of RAW264.7 cells into dendritic-like cells. Int J Clin Exp Pathol (2015) 0.80
Tumor-suppressive function of protein-tyrosine phosphatase non-receptor type 23 in testicular germ cell tumors is lost upon overexpression of miR142-3p microRNA. J Biol Chem (2013) 0.80
Role of MiR-126a-3p in Endothelial Injury in Endotoxic Mice. Crit Care Med (2016) 0.79
A systems biology approach to the analysis of subset-specific responses to lipopolysaccharide in dendritic cells. PLoS One (2014) 0.79
RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever. Nucleic Acids Res (2016) 0.78
Generation and Validation of miR-142 Knock Out Mice. PLoS One (2015) 0.78
Early life ozone exposure results in dysregulated innate immune function and altered microRNA expression in airway epithelium. PLoS One (2014) 0.78
MicroRNAs as potential therapeutics for treating spinal cord injury. Neural Regen Res (2012) 0.78
Reprogramming immune responses via microRNA modulation. Microrna Diagn Ther (2013) 0.77
Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer. Mol Ther (2014) 0.75
Low-dose plasmid DNA treatment increases plasma vasopressin and regulates blood pressure in experimental endotoxemia. BMC Immunol (2012) 0.75
MicroRNAs as regulatory elements in psoriasis. Open Med (Wars) (2016) 0.75
DNA Methylation Is Involved in the Expression of miR-142-3p in Fibroblasts and Induced Pluripotent Stem Cells. Stem Cells Int (2014) 0.75
Pigmy MicroRNA: surveillance cops in Therapies kingdom. Mol Med (2016) 0.75
The development and function of dendritic cell populations and their regulation by miRNAs. Protein Cell (2017) 0.75
TNF-α mRNA is negatively regulated by microRNA-181a-5p in maturation of dendritic cells induced by high mobility group box-1 protein. Sci Rep (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Dendritic cells and the control of immunity. Nature (1998) 56.54
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Identification of tissue-specific microRNAs from mouse. Curr Biol (2002) 34.55
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
MicroRNAs modulate hematopoietic lineage differentiation. Science (2003) 30.05
The pathophysiology and treatment of sepsis. N Engl J Med (2003) 21.67
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
The role of site accessibility in microRNA target recognition. Nat Genet (2007) 18.52
Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell (2005) 9.01
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
Regulation of adaptive immunity by the innate immune system. Science (2010) 8.00
Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol (2010) 7.75
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Inference of miRNA targets using evolutionary conservation and pathway analysis. BMC Bioinformatics (2007) 6.21
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med (2008) 5.97
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell (2008) 5.53
miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One (2007) 5.43
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol (2009) 5.05
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol (2006) 4.82
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest (1998) 4.77
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
TLRs and innate immunity. Blood (2008) 3.96
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Post-transcriptional control of cytokine production. Nat Immunol (2008) 3.30
When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity (2008) 3.15
Defective inflammatory response in interleukin 6-deficient mice. J Exp Med (1994) 2.92
AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell (2009) 2.75
Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat Cell Biol (2009) 2.63
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA (2007) 1.83
Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood (2009) 1.79
Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1. Mol Cell Biol (2006) 1.77
Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des (2003) 1.42
MicroRNAs distinguish translational from transcriptional silencing during endotoxin tolerance. J Biol Chem (2010) 1.36
A constitutive decay element promotes tumor necrosis factor alpha mRNA degradation via an AU-rich element-independent pathway. Mol Cell Biol (2003) 1.29
Ectopic expression of toll-like receptor-3 (TLR-3) overcomes the double-stranded RNA (dsRNA) signaling defects of P2.1 cells. J Interferon Cytokine Res (2004) 0.86
Differential effects of IL-6 on systemic and central production of TNF: a study with IL-6-deficient mice. Cytokine (1997) 0.86
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The Sorghum bicolor genome and the diversification of grasses. Nature (2009) 14.62
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Graft-versus-host disease. Lancet (2009) 8.78
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc (2009) 6.71
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell (2009) 5.22
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Role of C5a in inflammatory responses. Annu Rev Immunol (2005) 4.38
The enigma of sepsis. J Clin Invest (2003) 4.32
Probabilistic model of the human protein-protein interaction network. Nat Biotechnol (2005) 3.99
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev (2010) 3.37
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Model of nonalcoholic steatohepatitis. Am J Clin Nutr (2004) 3.13
The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol (2006) 3.11
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia (2007) 3.06
The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol (2003) 3.01
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics (2011) 2.74
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Adverse functions of IL-17A in experimental sepsis. FASEB J (2008) 2.60
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature (2007) 2.56
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res (2005) 2.55
Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol (2002) 2.50
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41
HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics (2010) 2.41
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res (2005) 2.31
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
A genome-wide characterization of microRNA genes in maize. PLoS Genet (2009) 2.23
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Pathophysiology of graft-versus-host disease. Semin Hematol (2006) 2.21
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood (2008) 2.21
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med (2006) 1.95
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A (2007) 1.91
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
The complement system. Cell Tissue Res (2010) 1.86
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood (2007) 1.79